Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress [Yahoo! Finance]
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Barclays PLC from $42.00 to $33.00. They now have an "equal weight" rating on the stock.
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss [Yahoo! Finance]